Leading Edge Genomic Services & Solutions

Novogene unveils intelligent Next Generation Sequencing delivery platform – Falcon

New platform drives industry forward and opens up a new era for NGS technology

Novogene recently announced Falcon, the first intelligent delivery platform for high-throughput Next Generation Sequencing (NGS). This platform represents a breakthrough in traditional NGS and will shape NGS industry standards and drive the future development of the NGS ecosystem. It will provide customers with an intelligent, efficient and robust service to help meet their sequencing requirements.

“Leveraging our years of expertise in genomic sequencing has enabled Novogene to develop and launch the first intelligent multi-product NGS delivery platform, which will provide a cutting-edge sequencing solution for customers. As a safe and accurate one-stop ground-breaking solution, Falcon enables faster delivery with a more stable quality. As a leading provider of genomic services and solutions in the world, we want to be better positioned to drive innovation in the industry, to lead the industry in the direction towards becoming digital and automated, to propel the establishment of industry standards, and to eventually achieve intelligent transformation”, said Dr. Li Ruiqiang, founder and CEO of Novogene.

Setting a new benchmark for NGS with intelligent technologies

Being intelligent is the cornerstone of Falcon. Over the years, NGS has become the mainstream commercial sequencing method thanks to its high throughput, fast sequencing speed, high flexibility and versatility. However, traditional NGS processes require manual or semi-manual operation by lab workers.

Falcon automates and optimizes NGS procedures. It’s designed to eliminate silos and blockages in NGS operations, from sample extraction and quality control to library preparation, library quality control, library pooling, and all the way to bioinformatics analysis.

Through this intelligent automation, Falcon is able to realize the concurrent delivery of four product types (WGS, WES, RNA-seq and library construction) and significantly improve the delivery cycle and data quality. In the future, more product types will be added.

Falcon’s platform is based on efficient data transmission and machine recognition to achieve accurate control, real-time monitoring and dynamic optimization of production, to ensure 24-hour round-the-clock production.

Creating a breakthrough delivery cycle and scale with a higher efficiency

The key advantage of Falcon is efficiency. The fully automated delivery platform processes samples far more efficiently than traditional human-assisted, single-process and semi-automated production lines. It can process 2,000 to 3,000 full-process samples a day, reducing the production cycle by an average of 60%. Its automated design ensures efficient 24-hour operations and guarantees the production cycle of major projects. For example, it takes 16 days from library construction to data delivery for a RNA-seq library construction project for a research institute with 500 standard samples using traditional methods. Falcon can do this in 90 hours.

Falcon can further improve efficiency through workforce management, reducing labor costs by up to 70% and doubling output stability. Through digital innovation, Novogene will unleash staff productivity to focus on developing many more innovative solutions.

Ensuring a reliable quality with a more stable performance

Reliability and stability are at the core of Falcon’s competitiveness. Sample contamination is a major problem affecting the accuracy of sequencing results in NGS. As an intelligent and fully automated production line, Falcon ensures extremely high reliability and stability throughout the process. The platform uses machine analysis to analyze and differentiate samples without human intervention. This avoids contamination in the sequencing process leading to an accuracy of up to 99.99%.

Falcon adopts two quality control steps: one is in the sample extraction step, and the other is in the library quality control step. It automatically chooses and matches the corresponding standards for different products, and simultaneously performs data recognition and diagnosis. All the sequencing results are evaluated by machine to ensure objectivity and effectiveness wherever possible. Combined with a stable production process this helps to increase the pass rate of NGS library construction by 5%.

To ensure full traceability throughout the production process a unique tracking code is generated for each sample. This enables customers to check a project’s progress at any time.

Novogene will continue to migrate more product lines to Falcon. This will be alongside new product launches and upgrading infrastructure to increase throughput and capacity. By leveraging its many years of expertise, Novogene will continue to explore push the boundaries of NGS and help to define industry standards, to strive for breakthroughs in productivity, stability and quality.

About Novogene

Founded in 2011, Novogene is a leading provider of genomics services and solutions in the world. Headquartered in Beijing, Novogene is doing business in over 60 countries and regions across 6 continents, serving over 4,000 clients. As the leader of genomic sequencing industry in China, Novogene provides services for fundamental researches in life sciences, for medical researches and technologies, and for library construction and sequencing platform building. We also provides sequencing, mass spectrometry (MS) and bioinformatics services for research universities, research institutes, hospitals, drug developers, and agricultural enterprises around the world.

As China gets back to work, Novogene announces scaling of sequencing services on Oxford Nanopore PromethION

As researchers from the broad scientific community in China are able to resume their research, Novogene, the global genome sequencing service provider, has announced that it will be scaling up its provision of sequencing services using Oxford Nanopore’s high throughput device, PromethION .

Oxford Nanopore and Novogene will collaborate to expand the types of application available using nanopore sequencing, to take advantage of nanopore’s rich data and ability to sequence short to ultra-long fragments of DNA/RNA. Having performed initial validation and testing on the PromethION in 2019, Novogene will start expanding services on a fleet of three PromethIONs, with a view to scaling up in the future. Novogene will offer applications including de novo genome assembly, bulk and single cell/nucleus full-length transcriptome sequencing, human genome resequencing and metagenomics.

Gordon Sanghera, CEO of Oxford Nanopore said, “We are pleased to support Novogene as a global powerhouse in genomics sequencing service. We are particularly excited to support the flourishing of new applications that take advantage of good value, high yields of longer reads.”

Ruiqiang Li, CEO of Novogene said, “We’re delighted to participate in the construction of the nanopore sequencing application ecosystem. We will keep providing advanced and tailored long-read genomic solutions to our customers based on this collaboration.“

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise, and the most advanced sequencing capacity in the world.

Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals. The company has become a world-leader in NGS services, with about 2,400 employees and multiple locations across the globe. Novogene’s depth of experience has resulted in the ownership of 29 NGS-related patents, as well as the publishing of over 517 research papers in collaboration with customers, often in well-respected publications such as Nature and Science.

Oxford Nanopore’s PromethION 48 device offers the only technology capable of sequencing long (or even ultra-long 1Mb +) fragments of DNA. The modular design of the PromethION allows for multiple experiments to be conducted at once, allowing for both scale and flexibility of use. One PromethION device can deliver more than 7 Tb of sequence data in a single run of 48-flow cells.

Novogene & NanoCellect partner to deliver single cell solutions to China

San Diego, Calif., January 6, 2020 — NanoCellect Biomedical Inc., a leader in the development and manufacture of microfluidic cell sorting solutions for cell-based assays, today announced a distribution and partnership agreement with China-based Novogene to distribute NanoCellect’s WOLF® Cell Sorter, N1 Single-Cell Dispenser, consumables and software in China. In addition, Novogene will be adding the WOLF platform to advance their leading edge genomic services and solutions business.

NanoCellect’s microfluidic solutions allow researchers to analyze and separate biological samples one cell at a time, enabling researchers to isolate cells or populations of interest from the rest of the sample more gently than conventional technology.

“As we expand our distribution of our products globally, Novogene was an obvious choice to partner with in China. Their leading global position providing sequencing and single cell services, combined with their ability to distribute, service and support researchers in China make Novogene an excellent partner for NanoCellect,” said Chris Neary, CEO Of NanoCellect Biomedical, Inc. “As we continue to expand our international distribution channels, we look forward to partnering with Novogene to bring gentle single-cell sorting solutions to their customers and helping to advance research at the cellular level.”

“NanoCellect’s microfluidic cell sorting technology is very innovative, and we’re delighted to be adding their product offerings growing list of technology solutions for our customer base,” said Ruiqiang Li, Ph.D., founder and CEO of Novogene.

For more information about NanoCellect’s and its products, please visit, nanocellect.com. For more information about Novogene, please visit, en.novogene.com.

About NanoCellect Biomedical, Inc.

NanoCellect is a life science tools company that develops and manufactures innovative solutions for cell analysis and sorting based on microfluidic technology. NanoCellect’s WOLF® Cell Sorter and N1 single-cell plate dispenser provide gentle sorting to maintain cell viability. The WOLF® platform is used in a growing list of application areas including antibody discovery, cell line development, genomic sample preparation, CRISPR genomic editing and plant, and animal genomics. Founded in 2009, NanoCellect is headquartered in San Diego, CA. For more information, please visit nanocellect.com.

About Novogene

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise, and more advanced sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals. The company has become a world-leader in NGS services, with 2,600 employees and multiple locations across the globe. Novogene’s depth of experience has resulted in the ownership of 27 NGS-related patents, as well as the publishing of over 4920 customer research papers, often in well-respected publications such as Nature and Science ,visit en.novogene.com/.

Novogene Europe Relocates its Sequencing Centre to Cambridge Science Park

CAMBRIDGE, UK, Oct 17, 2019 – Novogene Europe has upgraded and relocated its first European Sequencing Centre to TusPark UK’s new Bio-Innovation Centre in the Cambridge Science Park. The grand opening ceremony of Novogene’s new facility was held at 2 pm, 11th October 2019.

The move to the Bio-Innovation Centre has enabled Novogene’s Cambridge Sequencing Centre to expand its operation and continue to provide unsurpassed turnaround times and guaranteed data quality. With a professional team recruited from all over the world, the Centre offers leading-edge Next Generation Sequencing (NGS) services and solutions for all types of projects. The lab is now equipped with a variety of platforms, including an automatic system for library preparation, multiple NovaSeq 6000s and High Performance Computing Clusters. Novogene Cambridge Sequencing Centre is now capable of performing more than 280,000 human WGS analysis per year.

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise, and more advanced sequencing capacity in the world. The Novogene Europe subsidiary was established in 2014 to address the European market for NGS and expand Novogene’s business in Europe. Novogene Europe now provides leading edge services and solutions to customers in over 30 countries in Europe.

Novogene’s comprehensive service offering at its Cambridge Sequencing Centre includes human genome sequencing, plant and animal genome sequencing, transcriptome sequencing, metagenome sequencing, and lanes sequencing. Additional services are planned for the near future enabling Novogene Europe to provide even more optimized solutions for clients based on their research goals.

Ms. Tingting Zhou, the general manager of Novogene Europe, said, “The relocation of Novogene Cambridge Sequencing Centre helps us to improve our services, which is a significant development milestone of Novogene Europe. This means that we can deliver higher levels of NGS services and help our clients to solve the practical problems in their research. Our customers encouraged us to expand our services as we have always been trying to maximize the benefits for our customers. I also believe that our Cambridge Sequencing Centre will continue to thrive.”

“We are delighted to welcome Novogene to the Bio-Innovation Centre,” said Dr. David Chaplin, TusPark UK’s General Manager of the Bio-Innovation Centre. “Emerging technologies like NGS play critical roles in human health, environmental protection, plant and animal breeding and microbial remediation. The relocation of Novogene Cambridge Sequencing Centre is a fantastic new addition to the Cambridge Science Park. It’s our pleasure to establish a long-term relationship and grow together with Novogene.”

About Novogene Europe

Novogene Europe, established in 2014, is a Subsidiary of Novogene. It makes significant contributions to advancing human heath, agriculture, and environmental protection. Over 300 scientific research institutes and biotechnology companies in Europe rely on the powerful technologies and services of Novogene Europe. With leading-edge platforms, well developed bioinformatics pipelines, extensive experience in NGS, and the support from skilled employees, Novogene Europe has become the most competitive NGS provider in Europe.

About Cambridge Science Park

The Cambridge Science Park was established in 1970 by Trinity College – the largest of the colleges of the University of Cambridge. Trinity owns the freehold of the Cambridge Science Park which comprises 1.7 million sq ft of high technology and laboratory buildings set in 152 acres of mature parkland. Today, the Park is home to 7000 people at over 130 companies ranging from exciting start-ups to some of the world’s leading technology businesses.

Contact:

Ms. Tingting Zhou
General Manager
Novogene Europe
tingting.zhou@novogene-europe.com

Dr. Yan Wang
Tuspark UK
Operations Manager
yan.wang@tuspark.co.uk

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

Chipscreen Biosciences Co., Ltd. (Chipscreen, Stock Symbol: 688321. SH) and Novogene Co., Ltd. (Novogene) recently announced a strategic partnership for companion diagnostics (CDx) development. Under the agreement, Novogene will develop a CDx for Chipscreen’s anti-tumor drug candidate Chiauranib (CS2164), and will provide molecular testing services during Chipscreen’s clinical trials on Chiauranib.

Chiauranib is a multi-kinase inhibitor designed and developed by Chipscreen to target several novel molecules in three signaling pathways. Its anti-tumor effects stem from the simultaneous inhibition of angiogenesis and mitosis as well as the modification of the tumor microenvironment. According to the agreement, Chipscreen will leverage Novogene’s professional CDx development team and its CAP-accredited lab in Tianjin, China, to accelerate the clinical development of Chiauranib. “The collaboration between Chipscreen and Novogene will help select the right patients for the clinical development of Chiauranib in several tumor types, including ovarian cancer, small cell lung cancer, liver cancer, and non-Hodgkin’s lymphoma.” Said Dr. Zhiqiang Ning, Executive Vice President of Chipscreen, “In the US and many European countries, the co-development of innovative therapeutics and companion diagnostics is already a common practice because it has proven to increase the efficiency and success rate of drug development. We really hope our partnership with Novogene will help implement this idea and practice in China to benefit more patients faster.”

CDx not only increases the efficiency and success rate of drug development, but also makes treatment more personalized and effective. This is particularly important in the development of targeted therapies and immunotherapies in oncology. “Novogene offers a one-stop-shop molecular CDx development platform, has the experience of successfully developing and registering oncology in vitro diagnostics in China and operates a diagnostics sales network that covers the entire domestic market. We are thus perfectly positioned to provide pharma partners with comprehensive, value-added CDx services.” Said Dr. Jeff Cheng, Chief Scientific Officer of Novogene, “This partnership between two companies that are each leading player in their own field is an exciting joint effort on the orchestrated development, registration and commercialization of an innovative targeted therapy and its CDx in China.”

About Chipscreen

In 2001, Chipscreen Biosciences was founded in Shenzhen, specializing in the research and development of original small molecule drugs. With the self-created “integrated drug discovery and early evaluation platform based on chemical genetics” as its core competitiveness, Chipscreen Biosciences has now become one of China’s leading innovative drug enterprises, forming a modern biomedicine group company in Shenzhen, as its headquarters / research and development center / GMP production base, Chengdu, as a regional headquarter / research and development center / GMP production base, Beijing clinical research center and Shanghai commercial center. At present, the company has developed a number of original new drug product lines for tumors, diabetes, and endocrine and autoimmune diseases. In December 2014, the original anti-tumor new drug Chidamide was approved by the China Food and Drug Administration for marketing. Shenzhen Chipscreen Biosciences Co., Ltd. (Stock Symbol: 688321.SH) has been listed on the SSE STAR Market on August 12, 2019.

About Novogene

Founded in March 2011 in Beijing Zhonguangcun Life Science Park, Novogene specializes in the application of cutting-edge molecular biology technologies and high-performance computing in life science research and human health. Currently providing services to clients in more 60 countries and 6 continents, Novogene has become a global leader in the field of genomic sequencing and bioinformatics services.
With a deep understanding of the drug R&D process, rich project management experience and a strong commitment to data quality, Novogene provides fully integrated services for preclinical, translational, clinical and diagnostic R&D needs from pharmaceutical companies across the world in our strategically located CAP-accredited and CLIA-certified labs across the globe.

Mission Bio Launches in China, Announces Distribution Partnership with Novogene

Deal brings single-cell genomics to China and accelerates Mission Bio’s mission to predict and prevent cancer relapse on a global scale

SOUTH SAN FRANCISCO, Calif. (July 10 2019) Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, today announced that it has launched sales in China through a distribution agreement with Novogene, a leading provider of genomic services and solutions globally. The deal brings the Mission Bio Tapestri® Platform to the rapidly expanding Chinese market.

China is one of the world’s largest next-generation sequencing (NGS) markets, with enormous opportunities for genomics. Thanks to greater investment into the region’s healthcare infrastructure, the market is poised to explode: recent reports project the country’s DNA sequencing market will reach $2.7 billion by 2022, up from $1.1 billion in 2017. Further, the in vitro diagnostics (IVD) market is expected to double by 2022, growing from $3 billion in 2017.

“The demand for innovative and impactful technologies has required Novogene to bring new products to our customers,” said Ruiqiang Li, Ph.D., founder and CEO of Novogene. “The Mission Bio Tapestri Platform has advantages over current offerings, including increased resolution down to 0.1 percent. It is synergistic to the sequencing we offer, and we are excited to be able to offer this unique technology to our customers.”

The Mission Bio Tapestri Platform is the only single-cell targeted DNA solution available to more precisely identify cancer cell mutation profiles. Tapestri’s unique ability to sensitively detect rare cancer subclones and co-occurring cancer mutations offer a precise way to measure therapy response and disease progression.

“We are excited about our partnership with Novogene and increasing our reach into the China market,” said Darrin Crisitello, Chief Commercial Officer of Mission Bio. “Novogene is highly regarded globally across the industry with reach into key accounts that will have significant interest in the Tapestri Platform. The adoption of this targeted single-cell DNA analysis has been strong in other parts of the world, and we expect the same uptake in the Chinese market.”

Most recently, researchers at UCSF and Penn leveraged the single-cell technology to track and monitor cancer evolution, revealing the potential for more impactful, dynamic therapies in patients with Acute Myeloid Leukemia (AML). The study, published in Cancer Discovery, is the first-ever study using single-cell DNA analysis to reveal how cancer evolves in response to targeted treatment.

To learn more about Mission Bio and how it’s moving precision medicine forward, visit missionbio.com.

About Mission Bio

Mission Bio delivers targeted solutions for high impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables and software, which plug seamlessly into existing NGS workflows. LabCorp’s Covance Drug Development business will be the first global contract research organization to offer services on the Mission Bio Tapestri Platform, supporting biopharmaceutical customers in their need for faster, more precise clinical trials.

The company’s Tapestri Platform was also honored as a Top 10 Innovation of 2018 by The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. With Mission Bio, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.

About Novogene Corporation

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 2,214 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.

Novogene Receives CAP accreditation for its Med NGS Clinical Lab in Tianjin, China

TIANJIN, CHINA – March 19, 2019 – Novogene, a leading provider of genomic services and solutions, announced today that the Tianjin Novogene Med Lab – NGS Clinical Lab for genomic testing has successfully renewed its CAP accreditation, passing rigorous on-site inspection by experts from the College of American Pathologists (CAP) in recognition of the high standards of excellence established since its first accreditation in February 2017.

The College of American Pathologists is a US non-governmental organization that is widely considered the leader in laboratory quality assurance. Based on standards and guidance from the Clinical & Laboratory Standards Institute (CLSI) and the Clinical Laboratory Improvement Amendments (CLIA) of 1988, the CAP has created detailed checklists containing a core set of requirements which apply to all areas performing laboratory tests and procedures. Through its laboratory quality solutions programs, the CAP improves patient safety and advances the quality of pathology and laboratory service through education, standard setting and ensuring laboratories meet or exceed regulatory requirements.

Founded on June 23rd, 2014, the Tianjin Novogene Med Lab – NGS Clinical Lab is a modern, large-scale and independent clinical laboratory established in accordance with the standards of provincial medical inspection institutes issued by the Ministry of Health in China. It was approved by the Municipal Health and Family Planning Commission in December 2014 for the application of clinical gene amplification technology. Since March 7th, 2016, the Med Lab has been operating according to the international authoritative clinical laboratory quality certification system-the CAP -and passed the professional on-site inspection by CAP experts on February 10th, 2017, making it the first CAP-accredited NGS clinical lab in mainland China. After two years of effective operation and continuous improvement of its quality system, the Tianjin Novogene Med Lab – NGS Clinical Lab has once again passed the on-site inspection and successfully maintained its CAP accreditation.

“With the renewal of our CAP accreditation, Novogene continues to be globally recognized as a high-quality clinical service provider,” said Dr. Jeff Cheng, Chief Scientific Officer and Global Head of BioPharmaceutical Services at Novogene. “We strive to offer our clients best-in-class genomic solutions to advance research in human health.”

Novogene’s continuing accreditation signals that the lab has achieved universally accepted benchmarks for the standardization and accuracy of its quality management system, experimental technique level, bioinformatics analyses and clinical interpretation ability. This achievement is an important milestone in further establishing Novogene as a leading global provider of genomic services and solutions.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services.

Novogene Receives CFDA Approval for NovoFocus NSCLC CDx Test

Beijing, China – August 15, 2018 – Tianjin Novogene Bioinformatics Technology Company LTD, a fully-owned subsidiary of Novogene Co., received CFDA approval for its NovoFocus NSCLC CDx Test today. This is a next-generation sequencing (NGS)-based diagnostic test that simultaneously analyzes tumor samples for multiple genomic mutations associated with several CFDA-approved targeted therapies for non-small cell lung cancer (NSCLC), which accounts for ~80% of all lung cancers in China.

The NovoFocus NSCLC CDx Test was developed on the Thermo Fisher Ion Proton™ sequencing platform (approved by CFDA as “DA8600” in January 2017 for the diagnosis of cancer and inherited diseases). The reagent kits for sample processing and library construction, as well as the data analysis and result reporting software system, were developed by Novogene. Following this CFDA approval, results from the sequencing and analysis of three genes, EGFR, ALK and ROS1, can be used to identify NSCLC patients who may be eligible for treatment by CFDA-approved targeted therapies Gefitinib (IRESSA®), Osimertinib (TAGRISSO®) and Crizotinib (XALKORI®), respectively. Results on the other three genes, KRAS, BRAF and PIK3CA, can be considered by clinicians together with other test results and the patient’s disease characteristics during clinical decision making.

Figure: CFDA announcement for the approval of the NovoFocus NSCLC CDx Test (red box: translated to English below)

Ion Proton™ is a registered trademark of Thermo Fisher; IRESSA® and TAGRISSO® are registered trademarks of AstraZeneca; and XALKORI® is a registered trademark of Pfizer.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Novogene Establishes its First European Genomic Sequencing Center in Cambridge, UK

Cambridge, UK – May 21, 2018 – Novogene, a leading global provider of genomics services and solutions, today announced its first genomic sequencing center in Europe. The Novogene UK Genomic Sequencing Center will be established at the Babraham Research Campus in Cambridge in the United Kingdom. The center will provide an important base for Novogene to serve its European customers and contribute to human health across Europe.

The Novogene UK Genomic Sequencing Center will be equipped with a full automation system and the latest Illumina NovaSeq and supercomputing platforms. Establishing this facility will enable Novogene to provide cutting-edge next-generation sequencing and bioinformatics services and solutions to scientists at European universities, research institutes, pharmaceutical companies, and biotechnology companies.

“We are proud to set up our first European laboratory at the Babraham Research Campus,” said Dr. Ruiqiang Li, Founder and CEO of Novogene. “Our UK lab is our first step towards addressing the increasing demand from our European customers and will help us contribute to advancing human health, environmental protection, and plant and animal breeding in the United Kingdom and the whole of Europe.”

Derek Jones, CEO of Babraham Bioscience Technologies, which is responsible for the management and development of the Babraham Research Campus added: “I am extremely pleased to welcome Novogene to the Babraham Research Campus. The role of genomics is rapidly evolving and the Cambridge Cluster has become a hub for innovation in this area, attracting leader organizations, like Novogene, to locate here. Close proximity to academic and commercial collaborateors – both on campus and within the wider cluster – is hugely beneficial to the organizations based here and results in innovative and ground-breaking research that will ultimately benefit us all.”

About Babraham Research Campus
Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus.

The Babraham Research Campus is distinct in its co-location of 60 bioscience companies with the Babraham Institute, a world-renowned research organization which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC).

The aim of the campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organizations. The campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

The campus is managed and developed by BBT on behalf of the BBT shareholders, BBSRC and the Babraham Institute. For more information please visit: www.babraham.com.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Contact:
Tingting Zhou
General Manager
Novogene Europe
zhoutingting@novogene.com

The Babraham Research Campus
Derek Jones
CEO
Babraham Bioscience Technologies Ltd
derek.jones@babraham.co.uk

The University Medical Center Groningen and Novogene Announce the Start of the 10K Metagenome Project

Groningen, Netherlands and Beijing, China – October 31, 2017 — A research group led by Professor Cisca Wijmenga from the University Medical Center Groningen (UMCG) and Novogene, a leading global provider of genomic services and solutions, today announced a partnership to start the 10K Metagenome Project to further study population-based metagenomics.

The 10K Metagenome Project is initiated by Professor Cisca Wijmenga, Professor Rinse Weersma, Associate Professor Jingyuan Fu, and Associate Professor Alexandra Zhernakova from UMCG. This project aims to analyze 10,000 gut microbiomes from a large, deeply phenotyped population-based cohort in the Netherlands by using next-generation sequencing to study interactions between the microbiome and exogenous and intrinsic host factors. This follows a successful proof of concept study that was published last year in Science (Zhernakova et al., 2016). As part of the partnership, Novogene will provide next-generation sequencing for stool samples collected by UMCG and deliver high-quality data for each metagenome.

“Metagenomic shotgun sequencing allows us to discover intrinsic and exogenous factors that correlate with shifts in the microbiome composition and functionality,” said Professor Cisca Wijmenga, Spinoza Prize winner at UMCG. “Combined with the 8000 phenotypes present in the biobank, this rich dataset will enhance our understanding of which strains and pathways prevent or cause disease, a first step in translational research”.

“By leveraging the largest sequencing capacity in the world as well as our rich experience with next-generation sequencing technology, Novogene is taking an active role in accelerating genomic studies from all over the world,” said Ms. Tingting Zhou, General Manager of Novogene Europe. “It’s a great honor to partner with distinguished scholars from UMCG on the 10K Metagenome Project. This unprecedented study will shed more light on gut metagenomics, and therefore provide a better understanding of human health. We are proud to be part of it.”

About UMCG
The University Medical Center Groningen (UMCG) was established in 2005 as a joint activity of the University of Groningen and the Academic Hospital Groningen (AZG). At present, the UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands. More than 12,000 employees provide patient care, are involved in medical education and performing cutting-edge scientific research, and are focused on “healthy and active aging”.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Contact:

Professor Cisca Wijmenga, UMCG
C.Wijmenga@umcg.nl

Professor Rinse Weersma, UMCG
r.k.weersma@umcg.nl

Weiyan Peng
Business Development Director
Novogene Europe
pengweiyan@novogene.com